J&J Advances Myeloma Domination Plan With Bispecific Tecvayli Approval

First-In-Class Approval In EU

 
• By Andrew McConaghie
  
Johnson_and_Johnson
J&J is aiming to dominate myeloma with the addition of Tecvayli, the first bispecific antibody approved in the field.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip